A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment

Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment

The purpose of this study is to measure how much of the drug gets into the bloodstream and how long it takes the body to remove it when given to participants with hepatic (liver) impairment compared to participants with normal hepatic function. Information about any side effects that may occur will also be collected. This study will last approximately 28 days, not including screening.

Inclusion Criteria:

• Participants have given written informed consent approved by the ethical review board (ERB) governing the site
• Female participants should be of non-childbearing potential
• Have a body mass index (BMI) of 18 to 40 kilograms per square meter (kg/m^2)
• Healthy participants have normal hepatic function as determined by medical history, physical examination, and other screening procedures
• Individuals with hepatic impairment classified as Child-Pugh score A, B, or C (mild, moderate, or severe impairment)

Exclusion Criteria:

• Has had esophagus variceal bleeding within 3 months of check-in
• Have the need to take medications that may interfere with how the liver removes the drug
• Have evidence of cancer in the liver
• Consumes excessively large amounts of drinks with caffeine or alcohol